Compare CVS Health Corp (CVS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Recursion Pharmaceuticals Inc — how do they compare? CVS Health Corp trades at $93.57 (market cap $119.58B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.81B). The key difference: CVS Health Corp is far larger — about 66.1× Recursion Pharmaceuticals Inc's market cap, and CVS Health Corp pays a 2.84% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CVS | RXRX | |
|---|---|---|
Market Cap | $119.58B | $1.81B |
Sector | Health | Health |
52-Week High | $110.60 | $6.79 |
52-Week Low | $65.51 | $2.84 |
Enterprise Value | $181.93B | $1.33B |
Dividend Yield | 2.84% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
